Inspire Medical Systems (NYSE:INSP) Updates FY 2025 Earnings Guidance

Inspire Medical Systems (NYSE:INSP - Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided EPS guidance of 2.200-2.300 for the period, compared to the consensus EPS estimate of 2.160. The company issued revenue guidance of $940.0 million-$955.0 million, compared to the consensus revenue estimate of $949.2 million.

Inspire Medical Systems Stock Down 0.1 %

Shares of NYSE:INSP traded down $0.14 during midday trading on Monday, reaching $159.67. The company's stock had a trading volume of 735,091 shares, compared to its average volume of 584,935. Inspire Medical Systems has a 12-month low of $123.00 and a 12-month high of $256.11. The firm has a market capitalization of $4.75 billion, a P/E ratio of 92.29, a PEG ratio of 2.86 and a beta of 1.39. The firm has a 50 day moving average of $160.65 and a 200-day moving average of $179.55.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.33. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. On average, research analysts predict that Inspire Medical Systems will post 2.16 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on INSP shares. Stifel Nicolaus lowered their target price on Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a report on Monday, April 21st. Morgan Stanley cut their target price on shares of Inspire Medical Systems from $230.00 to $220.00 and set an "overweight" rating for the company in a research report on Tuesday, February 11th. Robert W. Baird decreased their price target on shares of Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 11th. Piper Sandler dropped their price target on shares of Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Finally, Truist Financial reduced their price objective on Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating for the company in a research note on Tuesday, February 11th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $218.90.

Insider Activity at Inspire Medical Systems

In other Inspire Medical Systems news, insider Randy Ban sold 25,584 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the transaction, the insider now owns 7,259 shares in the company, valued at $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CTO John Rondoni sold 583 shares of the firm's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the completion of the sale, the chief technology officer now owns 10,424 shares of the company's stock, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is owned by corporate insiders.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.